Novo Nordisk Stock Slips as Sales Grow Less Than Expected
"The sales growth is driven by increasing demand for our GLP-1-based diabetes and obesity treatments, and we are serving more ...
Novo Nordisk Stock Rises After Earnings. Weight-Loss Drug Wegovy Sales Beat Estimates.
Ozempic sales were a bit lower than expected in the quarter at DKK 29.8 billion, while Wegovy sales were higher at DKK 17.3 ...
ENDPOINTS NEWS51m
At this year's Obe­si­ty­Week, GLP-1s aren’t the on­ly talk of the town
As the GLP-1 class has taken over in recent years, a once-fringe conference has come into the spotlight for the biopharma industry. ObesityWeek, which started in 2013, attracted ...